21/09/2026 - Campus Can Ruti, CARE, Institutional, Success Stories

'Consorci Oncològic Integral Nord Catalunya' launched: a strategic alliance to bring european excellence in cancer care closer to nearly two million people

Six leading institutions are joining forces across healthcare, research, education and innovation to create one of southern Europe's strongest cancer ecosystems. The new Consorci Oncològic Integral Nord Catalunya aims to achieve European certification as a Comprehensive Cancer Consortium and join the European network of excellence in oncology.

01/07/2026 - Campus Can Ruti, Institutional, Success Stories

19 IGTP researchers, recognised in a scientific impact ranking

A total of 19 women researchers affiliated with the Germans Trias i Pujol Research Institute (IGTP) feature in the April 2026 edition of the Ranking of Spanish Women Researchers and Women Researchers in Spain, reflectig the relevance of the research conducted both at the institute and across the Can Ruti Campus.

02/03/2026 - Outreach, Success Stories

IGTP researchers take part in the 8th edition of #científiques bringing science closer to schools

For the fourth consecutive year, researchers from IGTP are taking part in the #científiques initiative, bringing science closer to schools and creating female role models in the framework of the International Day of Women and Girls in Science (11 February).

22/12/2025 - Campus Can Ruti, Research

A new study explores why the same mutation in the BRAF gene leads to different therapeutic responses to its inhibitors in melanoma and colorectal cancer

Researchers from the B·ARGO at IGTP and ICO have conducted a comparative analysis of the impact of BRAF gene mutations in melanoma and colorectal cancer, published in the journal BBA Reviews on Cancer.

05/12/2025 - Campus Can Ruti, CARE, Conferences

The CARE Annual Meeting reviews the program’s cancer research activity and sets priorities for the months ahead

The III CARE Annual Meeting, held on 5 December at BCIN, brought together the cancer research community of the Can Ruti Campus for a day focused on scientific dialogue, interdisciplinarity and future strategy.

04/12/2025 - Campus Can Ruti, Conferences, Innovation, Projects

IGTP drives collaborative science in health after three years of cooperation in biotechnology

The closing event celebrated on 17 November highlighted the work carried out and strengthened the commitment to maintain and expand the synergies created within the framework of the Plan. IGTP has contributed to several collaborative projects, focused on type 2 diabetes, breast cancer and medical databases.

27/11/2025 - Campus Can Ruti, CARE, Research

New study maps the landscape of KRAS mutations and targeted therapies in colorectal cancer

A team of researchers from IGTP and ICO has studied alterations in the KRAS gene in colorectal cancer by combining genomic analyses with a systematic review of targeted compounds and clinical trials. Their findings, published in the journal npj Precision Oncology, provide and updated overview to guide future advances in this cancer's treatment.

13/11/2025 - Campus Can Ruti, Outreach

Students from Badalona discover research at the Can Ruti Campus during Science Week

Nearly two hundred baccalaureate and vocational training students have taken part in a new edition of the activity "Open House: get to know the Can Ruti Campus up close", once again consolidating the campus's commitment to scientific outreach and to fostering vocations among young people.

30/09/2025 - Campus Can Ruti, Research, Success Stories

An international study opens the door to a new standard treatment for head and neck cancer

The combination of the drug nivolumab with chemotherapy improves survival in patients with high-risk head and neck cancer and could become the new standard treatment, according to the results of an international trial led by professionals from ICO, IGTP and IDIBELL.

25/09/2025 - Campus Can Ruti, Research

A group of genes could anticipate the response to a key breast cancer treatment

A study coordinated from Badalona by IrsiCaixa, the Catalan Institute of Oncology and the Germans Trias i Pujol Research Institute (within the CARE programme) has identified KIMA, a genomic signature that makes it possible to anticipate which patients with HR+/HER2- breast cancer will respond less well to CDK4/6 inhibitors. The finding, published in the journal Clinical and Translational Medicine, may help personalize therapies and design new combinations.